Cargando…

Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhy...

Descripción completa

Detalles Bibliográficos
Autores principales: Henen, Christine, Johnson, Elise A, Sokol, Sergio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561532/
https://www.ncbi.nlm.nih.gov/pubmed/37818120
http://dx.doi.org/10.7759/cureus.46612
_version_ 1785117944694439936
author Henen, Christine
Johnson, Elise A
Sokol, Sergio
author_facet Henen, Christine
Johnson, Elise A
Sokol, Sergio
author_sort Henen, Christine
collection PubMed
description Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhythmias and an increased risk of stroke. Patients with HOCM are at an increased risk of stroke due to the development of atrial fibrillation (AFib), a common arrhythmia observed in HOCM. AFib can result in the formation of blood clots in the atria, which may subsequently embolize the brain, causing a stroke. However, not all HOCM patients develop persistent AFib, leading to uncertainty regarding the appropriate management of stroke prevention in these cases. This case study aims to explore the management of recurrent cerebrovascular events (CVA) in a patient with HOCM who does not have confirmed persistent AFib. The argument revolves around whether anticoagulation should be offered for secondary stroke prevention in HOCM patients without a confirmed diagnosis of persistent AFib.
format Online
Article
Text
id pubmed-10561532
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105615322023-10-10 Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation Henen, Christine Johnson, Elise A Sokol, Sergio Cureus Cardiology Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic cardiovascular disorder characterized by the thickening of the heart muscle, particularly the left ventricle. It is a leading cause of sudden cardiac death in young individuals. HOCM is associated with various complications, including arrhythmias and an increased risk of stroke. Patients with HOCM are at an increased risk of stroke due to the development of atrial fibrillation (AFib), a common arrhythmia observed in HOCM. AFib can result in the formation of blood clots in the atria, which may subsequently embolize the brain, causing a stroke. However, not all HOCM patients develop persistent AFib, leading to uncertainty regarding the appropriate management of stroke prevention in these cases. This case study aims to explore the management of recurrent cerebrovascular events (CVA) in a patient with HOCM who does not have confirmed persistent AFib. The argument revolves around whether anticoagulation should be offered for secondary stroke prevention in HOCM patients without a confirmed diagnosis of persistent AFib. Cureus 2023-10-07 /pmc/articles/PMC10561532/ /pubmed/37818120 http://dx.doi.org/10.7759/cureus.46612 Text en Copyright © 2023, Henen et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Henen, Christine
Johnson, Elise A
Sokol, Sergio
Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
title Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
title_full Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
title_fullStr Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
title_full_unstemmed Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
title_short Managing Stroke Prevention in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients Without Confirmed Persistent Atrial Fibrillation: A Dilemma of Anticoagulation
title_sort managing stroke prevention in hypertrophic obstructive cardiomyopathy (hocm) patients without confirmed persistent atrial fibrillation: a dilemma of anticoagulation
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561532/
https://www.ncbi.nlm.nih.gov/pubmed/37818120
http://dx.doi.org/10.7759/cureus.46612
work_keys_str_mv AT henenchristine managingstrokepreventioninhypertrophicobstructivecardiomyopathyhocmpatientswithoutconfirmedpersistentatrialfibrillationadilemmaofanticoagulation
AT johnsonelisea managingstrokepreventioninhypertrophicobstructivecardiomyopathyhocmpatientswithoutconfirmedpersistentatrialfibrillationadilemmaofanticoagulation
AT sokolsergio managingstrokepreventioninhypertrophicobstructivecardiomyopathyhocmpatientswithoutconfirmedpersistentatrialfibrillationadilemmaofanticoagulation